No connection

Search Results

OKYO vs QTI

OKYO
OKYO Pharma Limited
BEARISH
Price
$1.65
Market Cap
$86.6M
Sector
Healthcare
AI Confidence
95%
QTI
QT Imaging Holdings, Inc.
BEARISH
Price
$6.93
Market Cap
$83.5M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
OKYO
--
QTI
--
Forward P/E
OKYO
-8.25
QTI
--
P/B Ratio
OKYO
-18.54
QTI
12.79
P/S Ratio
OKYO
--
QTI
4.41
EV/EBITDA
OKYO
-9.5
QTI
-18.18

Profitability

Gross Margin
OKYO
0.0%
QTI
45.36%
Operating Margin
OKYO
0.0%
QTI
-8.46%
Profit Margin
OKYO
0.0%
QTI
-111.4%
ROE
OKYO
--
QTI
--
ROA
OKYO
-104.63%
QTI
-19.05%

Growth

Revenue Growth
OKYO
--
QTI
877.2%
Earnings Growth
OKYO
--
QTI
--

Financial Health

Debt/Equity
OKYO
--
QTI
0.81
Current Ratio
OKYO
0.58
QTI
2.81
Quick Ratio
OKYO
0.53
QTI
2.07

Dividends

Dividend Yield
OKYO
--
QTI
--
Payout Ratio
OKYO
0.0%
QTI
0.0%

AI Verdict

OKYO BEARISH

OKYO exhibits severe financial distress, anchored by a weak Piotroski F-Score of 2/9 and a critical liquidity position. The company's negative Price/Book ratio (-18.54) and an ROA of -104.63% indicate significant insolvency risk and a lack of tangible asset backing. While analysts maintain a speculative target price of $8.00, the fundamental data reveals a company unable to cover short-term obligations (Current Ratio 0.58) with no current revenue stream. The disconnect between the bullish analyst target and the bearish deterministic health scores suggests a high-risk speculative play rather than a value investment.

Strengths
Significant upside potential if analyst target of $8.00 is realized
Positive 1-year price performance (+47.3%)
Operating in the high-growth Biotechnology sector
Risks
Severe liquidity crisis with a Current Ratio of 0.58
Negative shareholder equity as evidenced by Price/Book of -18.54
Critical financial health (Piotroski F-Score 2/9)
QTI BEARISH

The company exhibits critical financial weakness with a Piotroski F-Score of 1/9, indicating severe fundamental distress. Despite an extraordinary YoY revenue growth of 877.20%, the company remains deeply unprofitable with a profit margin of -111.40% and a history of massive earnings misses. Technical trends are overwhelmingly bearish, characterized by a 78.7% price collapse over the last six months. While short-term liquidity is stable, the combination of poor health scores and negative earnings progression suggests a high risk of further devaluation.

Strengths
Explosive YoY revenue growth of 877.20%
Strong gross margin of 45.36% indicating product value
Healthy short-term liquidity with a Current Ratio of 2.81
Risks
Critical fundamental health as evidenced by Piotroski F-Score of 1/9
Severe net losses with a profit margin of -111.40%
Catastrophic price performance (-95.3% over 5 years)

Compare Another Pair

OKYO vs QTI: Head-to-Head Comparison

This page compares OKYO Pharma Limited (OKYO) and QT Imaging Holdings, Inc. (QTI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile